- ￥6930
- TargetMol
- 美国
- T38297
- 2025年07月14日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
零下80~20°C
- 保质期：
Powder: -20°C for 3 years In solvent: -80°C for 2 years
- 英文名：
Ribavirin-13C5
- 库存：
10
- 供应商：
TargetMol
- CAS号：
1646818-35-0
- 规格：
1 mg
Product Introduction
Bioactivity
英文名:Ribavirin-13C5
描述:Ribavirin-13C5is intended for use as an internal standard for the quantification of ribavirin by GC- or LC-MS. Ribavirin is an antiviral guanosine nucleoside analog.1,2Upon entry into cells, ribavirin is metabolized to an active triphosphate form that induces viral RNA chain termination and inhibits viral polymerases. It reduces replication in a panel of seven RNA and four DNA viruses in Vero cells (EC50s = 2-95 μg/ml).3Ribavirin also reduces replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Vero cells (EC50= 109.5 μM).4Aerosol administration of ribavirin (30 mg/kg) reduces mortality in a mouse model of influenza A infection.5Formulations containing ribavirin have been used in the treatment of respiratory syncytial virus (RSV), hepatitis C virus (HCV), and viral hemorrhagic fevers.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验with aerosolized ribavirin are available. Unfortunately, administration of palivizumab is restricted to at-risk infants up to the age of two and is associated with high cost, while ribavirin treatment is hindered by questionable efficacy and safety reasons
Nat Metab：李贵登等团队合作发现肿瘤内酸度维持 T 细胞干性影响肿瘤免疫治疗
录组学、代谢组学以及同位素（13C6-葡萄糖，13C16-棕榈酸）示踪技术发现，长期胞外酸处理能够抑制 mTOR 信号通路及糖酵解途径，促进 T 细胞内的脂肪酸氧化（FAO），增强线粒体适应性, 从而维持「干性样」T 细胞的代谢表征。进一步深入分析以及通过 13C5-甲硫氨酸代谢流实验，作者们发现胞外酸度的升高显著抑制了 T 细胞内的甲硫氨酸摄入及一碳代谢（甲硫氨酸循环）。 机制上，一方面，胞外酸处理通过抑制 MYC 的表达，降低 T 细胞表面甲硫氨酸转运体（SLC7A5）的表达，进而削弱 T 细胞对胞外
Methods for Monitoring Gene Gun-Induced HBV- and HCV-Specific Immune Responses in Mouse Models
on interferon and ribavirin can cure 45–85% of the treated HCV-infected patients largely depending on the viral genotype. New regimens including protease inhibitors will be introduced during 2011 and these will increase the cure rates for the hardest to treat
技术资料暂无技术资料 索取技术资料
